New drug cocktail shows promise for Tough-to-Treat myeloma
NCT ID NCT03590652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of four drugs (daratumumab, ixazomib, pomalidomide, and dexamethasone) in 23 people with multiple myeloma that had come back or stopped responding to earlier treatments. The goal was to see how many patients' tumors shrank or disappeared. The study was stopped early, but the results help doctors understand if this powerful mix can control the disease for a while longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California, Davis
Sacramento, California, 95817, United States
-
University of California, Los Angeles
Los Angeles, California, 90024, United States
-
University of California, San Francisco
San Francisco, California, 94115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat myeloma
- Can engineered immune cells outsmart Treatment-Resistant myeloma?
- Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
- A pre-treatment pill may supercharge cancer-fighting immune cells
- New antibody combo aims to stall multiple Myeloma's return
- Real-World data may reveal best Second-Line therapy for multiple myeloma